Thromboemolic events (TEE) incidences in trials of thalidomide plus anthracycline combination regimens without thromboprophylaxis.
| Regimen . | Disease Status . | TEE Incidence . | References . |
|---|---|---|---|
| *addition of ASA 81 mg/day decreased the incidence to 18% | |||
| **addition of enoxaparin 40 mg/day decreased the incidence to 24% | |||
| Abbreviations: CTX, cyclophosphamide; DOX, doxorubicin; DEX, dexamethasone; THAL, thalidomide; NDMM, newly diagnosed multiple myeloma; RRMM, relapsed/relapsed multiple myeloma; TEE, thromboembolic event | |||
| Liposomal DOX 30 mg/m2 d 1 Vincristine 2 mg d 1 DEX 40 mg daily d 1–4 THAL 50–400 mg/day | 55 NDMM 50 RRMM | 58%* | Baz et al5 |
| Total Therapy II Thalidomide 400 mg/day | NDMM | 34%** | Barlogie et al23 |
| Vincristine 1.5 mg d 1 Epirubicin 30 mg/m2 day 1–2 DEX 20 mg/m2 days 1–4 THAL 200–400 mg/day | NDMM | 26% | Schutt et al33 |
| DEX 40 mg/day d 1–4 THAL 400 mg/day Cisplatin 10 mg/m2 CIV d 1–4 CTX 400 mg/m2 CIV d 1–4 VP-16 40 mg/m2 CIV d 1–4 DOX 10 mg/m2 CIV d 1–4 | NDMM | 16% | Zangari et al36 |
| Liposomal DOX 40 mg/m2 d 1 Vincristine 2 mg d 1 DEX 40 mg daily d 1–4, 15–18 THAL ≥ 200 mg/day | NDMM | 10% | Zervas et al34 |
| Regimen . | Disease Status . | TEE Incidence . | References . |
|---|---|---|---|
| *addition of ASA 81 mg/day decreased the incidence to 18% | |||
| **addition of enoxaparin 40 mg/day decreased the incidence to 24% | |||
| Abbreviations: CTX, cyclophosphamide; DOX, doxorubicin; DEX, dexamethasone; THAL, thalidomide; NDMM, newly diagnosed multiple myeloma; RRMM, relapsed/relapsed multiple myeloma; TEE, thromboembolic event | |||
| Liposomal DOX 30 mg/m2 d 1 Vincristine 2 mg d 1 DEX 40 mg daily d 1–4 THAL 50–400 mg/day | 55 NDMM 50 RRMM | 58%* | Baz et al5 |
| Total Therapy II Thalidomide 400 mg/day | NDMM | 34%** | Barlogie et al23 |
| Vincristine 1.5 mg d 1 Epirubicin 30 mg/m2 day 1–2 DEX 20 mg/m2 days 1–4 THAL 200–400 mg/day | NDMM | 26% | Schutt et al33 |
| DEX 40 mg/day d 1–4 THAL 400 mg/day Cisplatin 10 mg/m2 CIV d 1–4 CTX 400 mg/m2 CIV d 1–4 VP-16 40 mg/m2 CIV d 1–4 DOX 10 mg/m2 CIV d 1–4 | NDMM | 16% | Zangari et al36 |
| Liposomal DOX 40 mg/m2 d 1 Vincristine 2 mg d 1 DEX 40 mg daily d 1–4, 15–18 THAL ≥ 200 mg/day | NDMM | 10% | Zervas et al34 |